Clinical trial
Real-World Study of Ceftazidime-Avibactam to Characterize the Usage in Clinical Practice
Name
C3591037
Description
This observational study will enroll approximately 450 in patients. Patients treated with CAZ AVI for at least 1 dose at around 20 research centers in China will be enroll.
Trial arms
Trial start
2022-10-20
Estimated PCD
2024-03-31
Trial end
2024-03-31
Status
Recruiting
Treatment
ceftazidime avibactam group
Non-Interventional Study
Arms:
ceftazidime avibactam group
Other names:
CAZ/AVI group
Size
450
Primary endpoint
Clinical success rate after ceftazidime-avibactam treatment initiation
Up to 1 year
Microbiologic success rate after ceftazidime-avibactam treatment initiation
Up to 1 year
Percentage of patients by demographic characteristics
Day 1
Percentage of patients by indication type
Day 1
Percentage of patients by source of infection
Day 1
Percentage of isolated strains
Day 1
Susceptibility of ceftazidime-avibactam
Day 1
The percentage of carbapenem-resistant organisms
Day 1
Percentage of Genotype
Day 1
Eligibility criteria
Inclusion criteria：
* Initiate ≥1 dose of ceftazidime-avibactam during hospitalization.
* Aged ≥ 18 years old at the time of the informed consent signature.
* Provide signed informed consent. Exclusion criteria：
* Are enrolled in any clinical trial, including enrollment in non interventional studies.
* Pregnant women.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'OTHER'}, 'enrollmentInfo': {'count': 450, 'type': 'ESTIMATED'}}
Updated at
2023-11-03
1 organization
1 product
3 indications
Organization
PfizerProduct
Ceftazidime AvibactamIndication
Hospital-Acquired PneumoniaIndication
Ventilator-associated pneumoniaIndication
Complicated Intra-Abdominal Infections